CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 110 enrolled
Drug / intervention
Fluviral®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00929331
NCT00929331Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years.

GlaxoSmithKline·interventional·Posted Jun 29, 2009·Updated Nov 9, 2020

In Brief

A Phase 3 clinical trial evaluating Fluviral® for Influenza, Human. Completed, enrolled 110 participants across 1 site.

Detailed Summary

This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 29, 2009
Enrollment StartJul 11, 2009
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 20 daysPosted 17.0 years ago

Interventions

Fluviral®biological

Intramuscular injection, one dose